Suzan Williams
Adult Health · Pismo Beach, CANPI 1447238894
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 418 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 418 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$979
- Novo Nordisk$860
- GSK$750
- Lilly USA, LLC$537
- Amgen$477
- plus $3K from 29 others
What the payments were for
- Food & beverage$8,056100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 115 | $1,823 |
| AstraZeneca | 38 | $979 |
| Novo Nordisk | 57 | $860 |
| GSK | 58 | $750 |
| Lilly USA, LLC | 17 | $537 |
| Amgen | 19 | $477 |
| Pfizer | 27 | $464 |
| Boehringer Ingelheim | 13 | $337 |
| Johnson & Johnson | 7 | $191 |
| Jazz Pharmaceuticals Inc. | 6 | $155 |
| Bayer | 7 | $140 |
| Biohaven Pharmaceuticals, Inc. | 11 | $129 |
| E.r. Squibb & Sons, L.L.C. | 1 | $109 |
| Inspire Medical Systems, Inc. | 1 | $107 |
| Radius Health, Inc. | 4 | $105 |
| Merck | 5 | $101 |
| Axsome Therapeutics, Inc. | 3 | $84 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $78 |
| SK Life Science, Inc. | 2 | $69 |
| Ardelyx, Inc. | 2 | $66 |
| Sunovion Pharmaceuticals Inc. | 3 | $63 |
| UCB, Inc. | 2 | $58 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $57 |
| Neurocrine Biosciences, Inc. | 2 | $56 |
| Teva Pharmaceuticals USA, Inc. | 2 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Bioventus LLC | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Corcept Therapeutics | 1 | $23 |
| Ascend Therapeutics US, LLC | 1 | $23 |
| Exact Sciences | 1 | $21 |
| Eisai Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Almatica Pharma LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,056 in reported general payments places this provider in the 95th percentile of 785 adult health providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 87 | $120,619 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $87,742 |
| FarxigaDapagliflozin Propanediol | 68 | $82,446 |
| JardianceEmpagliflozin | 59 | $75,177 |
| ProliaDenosumab | 40 | $68,978 |
| EliquisApixaban | 21 | $32,547 |
| MounjaroTirzepatide | 20 | $29,525 |
| TrulicityDulaglutide | 16 | $28,105 |
| XareltoRivaroxaban | 20 | $21,524 |
| JanuviaSitagliptin Phosphate | 15 | $17,903 |
| Repatha SureclickEvolocumab | 17 | $13,764 |
| TrulancePlecanatide | 12 | $7,240 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $5,619 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $5,431 |
| Atorvastatin Calcium | 316 | $3,907 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $860 | $120,61987 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $750 | $93,17473 claims |
| AstraZenecaFarxiga, Symbicort | $979 | $88,06579 claims |
| Boehringer IngelheimJardiance | $337 | $75,17759 claims |
| AmgenProlia | $477 | $68,97840 claims |
| Lilly USA, LLCMounjaro, Trulicity | $537 | $57,63036 claims |
| PfizerEliquis | $464 | $32,54721 claims |
| Johnson & JohnsonXarelto | $191 | $21,52420 claims |
| MerckJanuvia | $101 | $17,90315 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $16 | $7,24012 claims |
| AbbVieSynthroid | $1,823 | $1,83226 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $52 | $1,18312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 785 adult health providers in California.
Other adult health in Pismo Beach
- Karolina FaysmanLos Angeles$1.1M
- Linda BuckLos Angeles$170K
- Naomi PesynaAnaheim$141K
- Stacy GrissenEncinitas$82K
- Kimberly PodsadaSan Diego$78K
- Brenda PatrickSan Leandro$68K
- Brittany PolizziEncinitas$35K
- Nancy NicolosiLaguna Woods$31K
- Michele WestendorfNewport Beach$30K
- Lisa HinemanLos Angeles$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.